Novus Therapeutics, Inc.
19900 MacArthur Blvd., Suite 550
Irvine, California 92612
(949) 238-8090
August 7, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Irene Paik
| Re: | Novus Therapeutics, Inc. |
| Registration Statement on Form S-3 |
| Filed June 23, 2017 |
| File No. 333-218949 |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Novus Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-3 filed by the Company (the “Registration Statement”) be accelerated to 4:00 p.m., Eastern Daylight Time, on August 9, 2017 or as soon thereafter as practicable.
Please call Ryan Murr of Gibson, Dunn & Crutcher LLP at (415) 393-8243 as soon as the Registration Statement has been declared effective.
[Signature page follows]
| Very truly yours, |
| Novus Therapeutics, Inc. |
| /s/ Jon Kuwahara |
| Jon Kuwahara |
| Senior Vice President of Finance and Administration |
| cc: | Ryan A. Murr, Gibson, Dunn & Crutcher LLP |